# Galleri

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/galleri
Canonical HTML page: https://getyourbrief.com/entity/galleri

## Timeline

- **2026-03-22**: Market Outperformance — Grail shares end the week as a top performer in the healthcare sector, recouping major losses.
- **2026-03-18**: TD Cowen Upgrade — TD Cowen upgrades Grail to 'Buy,' arguing the market overreacted to the leadership change.
- **2026-03-13**: CEO Transition & Setback — CEO Bob Ragusa retires following reports of a clinical trial setback, causing a sharp drop in GRAL shares.

## Recent coverage (2 stories, network-wide)

### Grail Shares Outperform Market as Analysts Reassess Galleri Potential
2026-03-22 12:11:37 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2

Grail (GRAL) shares staged a significant recovery this week, outperforming the broader market following a period of heavy selling. The rebound was driven by a high-profile analyst upgrade and a shift in investor sentiment regarding the company's multi-cancer early detection (MCED) platform.
Full story: https://getbiobrief.com/story/grail-stock-rally-march-2026

### Grail Shares Surge as Analysts Call Recent Selloff a "Buying Opportunity"
2026-03-22 12:10:34 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2

Grail (GRAL) stock staged a major recovery this week, outperforming the broader market after a pivotal upgrade from TD Cowen. The rally marks a significant shift in investor sentiment following a volatile period triggered by a CEO transition and clinical trial concerns.
Full story: https://gethealthbrief.com/story/grail-stock-recovery-analysis-march-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.